FBIO and MBIO Related Headlines
Go Back- Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
- FDA grants orphan drug status to Mustang Bio's brain cancer treatment
- Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
FBIO and MBIO Related Press Releases
Go Back- Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
- Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
FBIO and MBIO Related SEC Filings
Go Back- Form 10-Q MUSTANG BIO, INC. For: Mar 31
- Form 4 MUSTANG BIO, INC. For: Apr 24 Filed by: Litchman Manuel MD
- Form 8-K MUSTANG BIO, INC. For: Apr 15
- Form 10-K MUSTANG BIO, INC. For: Dec 31
- Form SCHEDULE 13D/A MUSTANG BIO, INC. Filed by: Fortress Biotech, Inc.
- Form 4 MUSTANG BIO, INC. For: Jan 02 Filed by: Fortress Biotech, Inc.
- Form 4 MUSTANG BIO, INC. For: Dec 30 Filed by: Herskowitz Neil
- Form 4 MUSTANG BIO, INC. For: Dec 30 Filed by: Chill Adam J.
- Form 4 MUSTANG BIO, INC. For: Dec 30 Filed by: Jin David
- Form 8-K MUSTANG BIO, INC. For: Dec 17
- Form DEF 14A MUSTANG BIO, INC. For: Dec 22
- Form 10-Q MUSTANG BIO, INC. For: Sep 30
- Form SCHEDULE 13D/A MUSTANG BIO, INC. Filed by: Fortress Biotech, Inc.
- Form 4 MUSTANG BIO, INC. For: Sep 29 Filed by: Fortress Biotech, Inc.
- Form 424B5 MUSTANG BIO, INC.
- Form SCHEDULE 13G/A MUSTANG BIO, INC. Filed by: INTRACOASTAL CAPITAL, LLC
- Form 10-Q MUSTANG BIO, INC. For: Jun 30
- Form 8-K MUSTANG BIO, INC. For: Jul 07
